Technology evaluation: Colostrinin (ReGen)

Download

Full text not archived in this repository.

Advice

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Tools

Lists

Rattray, M. (2005) Technology evaluation: Colostrinin (ReGen). Current Opinion in Molecular Therapeutics, 7 (1). pp. 78-84. ISSN 1464-8431

Abstract/Summary

ReGen Therapeutics is developing Colostrinin, a polypeptide complex derived from ovine colostrums, for the potential treatment of Alzheimer's disease. The compound is currently undergoing phase II clinical trials.

Item Type	Article
URI	https://reading-clone.eprints-hosting.org/id/eprint/15727
Refereed	Yes
Divisions	Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology No Reading authors. Back catalogue items
Uncontrolled Keywords	Alzheimer Disease/drug therapy Animals Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Colostrum/chemistry Female Humans PC12 Cells Peptides/chemistry/metabolism/pharmacokinetics/therapeutic use Pregnancy Rats
Download/View statistics	View download statistics for this item

Deposit Details

Date Deposited:	09 Aug 2011 14:22	Date item deposited into CentAUR
Last Modified:	09 Jul 2023 01:57	Date item last modified

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar